• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Nicotinamide methylation in patients with cirrhosis.

作者信息

Cuomo R, Dattilo M, Pumpo R, Capuano G, Boselli L, Budillon G

机构信息

Cattedra di Gastroenterologia, Facoltà di Medicina, Università di Napoli Federico II, Italy.

出版信息

J Hepatol. 1994 Jan;20(1):138-42. doi: 10.1016/s0168-8278(05)80480-5.

DOI:10.1016/s0168-8278(05)80480-5
PMID:8201215
Abstract

Methylation reactions play an important role in the transformation of endogenous and exogenous substances. Up to 85% of all transmethylation reactions occur in the liver. Several studies have shown that these metabolic processes are greatly influenced by the presence of hepatic diseases. We investigated the methylation of nicotinamide in 16 control subjects and in 29 patients with cirrhosis (19 Child A, 10 Child B). The basal serum value of N-methyl-nicotinamide was measured in all subjects. In seven controls and in nine patients with cirrhosis (5 Child A and 4 Child B), the serum levels and urinary excretion (5 and 24 h) of N-methyl-nicotinamide were also evaluated after oral administration of nicotinamide (1.5 mg/kg body weight). The basal serum levels of N-methyl-nicotinamide were significantly (p < 0.05) higher in patients with cirrhosis (Child A: median 34 ng/ml, 16th percentile 24, 84th percentile 61; Child B median 45, 16th percentile 34, 84th percentile 81) than in controls (median 22, 16th percentile 13, 85th percentile 28). After the nicotinamide load the urinary excretion and the time course of serum N-methyl-nicotinamide in cirrhosis were also higher (p < 0.05) than in controls (24 h urinary excretion = 66.2 mg +/- 5 S.D. in cirrhosis; 47.2 +/- 10.3 in controls) (area under the serum concentration versus time curve = 68 micrograms.ml-1.min-1 +/- 22 S.D. in cirrhosis; 32 +/- 15 in controls). In conclusion, our results show that cirrhosis does not impair the efficiency of nicotinamide methylation.

摘要

相似文献

1
Nicotinamide methylation in patients with cirrhosis.
J Hepatol. 1994 Jan;20(1):138-42. doi: 10.1016/s0168-8278(05)80480-5.
2
The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production.人类肝硬化中烟酰胺的代谢:关于N-甲基烟酰胺和2-吡啶酮-5-甲酰胺生成的研究
Am J Gastroenterol. 2001 Apr;96(4):1183-7. doi: 10.1111/j.1572-0241.2001.03698.x.
3
Methylation of nicotinamide in rat liver cytosol and its correlation with hepatocellular proliferation.大鼠肝细胞溶胶中烟酰胺的甲基化及其与肝细胞增殖的相关性。
Biochim Biophys Acta. 1982 Dec 17;719(3):518-26. doi: 10.1016/0304-4165(82)90241-0.
4
Nicotinamide methylation and hepatic energy reserve: a study by liver perfusion in vitro.
J Hepatol. 1995 Oct;23(4):465-70. doi: 10.1016/0168-8278(95)80206-1.
5
Metabolic effects of nicotinamide administration in rats.
J Nutr. 1983 Feb;113(2):215-21. doi: 10.1093/jn/113.2.215.
6
Nicotinamide methylation. Tissue distribution, developmental and neoplastic changes.烟酰胺甲基化。组织分布、发育及肿瘤性变化。
Biochim Biophys Acta. 1984 Sep 28;801(2):259-64. doi: 10.1016/0304-4165(84)90075-8.
7
Fluorometric assay of nicotinamide methyltransferase with a new substrate, 4-methylnicotinamide.
Chem Pharm Bull (Tokyo). 1989 Dec;37(12):3330-2. doi: 10.1248/cpb.37.3330.
8
Substrate specificity of nicotinamide methyltransferase isolated from porcine liver.从猪肝中分离出的烟酰胺甲基转移酶的底物特异性
Arch Biochem Biophys. 1988 Feb 1;260(2):601-8. doi: 10.1016/0003-9861(88)90487-0.
9
N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test.帕金森病中氮杂环胺的N-甲基化能力更高:烟酰胺负荷试验。
J Neural Transm (Vienna). 2000;107(8-9):985-95. doi: 10.1007/s007020070047.
10
Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis.N(1)-甲基烟酰胺的肾清除率:肝硬化肝功能障碍严重程度的敏感标志物。
Nephron. 2000 Jan;84(1):32-9. doi: 10.1159/000045536.

引用本文的文献

1
Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets.烟酰胺N-甲基转移酶(NNMT)与肝癌:从代谢网络到治疗靶点
Biomolecules. 2025 May 14;15(5):719. doi: 10.3390/biom15050719.
2
Exploring NNMT: from metabolic pathways to therapeutic targets.探索NNMT:从代谢途径到治疗靶点。
Arch Pharm Res. 2024 Dec;47(12):893-913. doi: 10.1007/s12272-024-01519-9. Epub 2024 Nov 28.
3
Nicotinamide N-methyltransferase and liver diseases.烟酰胺N-甲基转移酶与肝脏疾病
Genes Dis. 2022 Apr 20;10(5):1883-1893. doi: 10.1016/j.gendis.2022.03.019. eCollection 2023 Sep.
4
Nicotinamide -Methyltransferase in Health and Cancer.健康与癌症中的烟酰胺 - 甲基转移酶
Int J Tryptophan Res. 2017 Jun 30;10:1178646917691739. doi: 10.1177/1178646917691739. eCollection 2017.
5
Nicotinamide -Methyltransferase: Genomic Connection to Disease.烟酰胺甲基转移酶:与疾病的基因组关联
Int J Tryptophan Res. 2020 Jun 4;13:1178646920919770. doi: 10.1177/1178646920919770. eCollection 2020.
6
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.单次口服佩非替尼(ASP015K)在肝功能正常和受损的日本受试者中的药代动力学及安全性
Clin Pharmacol Drug Dev. 2020 Aug;9(6):699-708. doi: 10.1002/cpdd.751. Epub 2019 Dec 12.
7
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.一项评估不同程度肝功能损伤的晚期癌症患者中贝林司他的药代动力学的 I 期研究。
Br J Clin Pharmacol. 2019 Nov;85(11):2499-2511. doi: 10.1111/bcp.14054. Epub 2019 Sep 4.
8
Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma.烟酰胺N-甲基转移酶过表达与Akt磷酸化相关,并提示鼻咽癌患者预后较差。
Tumour Biol. 2013 Dec;34(6):3923-31. doi: 10.1007/s13277-013-0980-z. Epub 2013 Jul 11.
9
Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis.烟酰胺N-甲基转移酶在肝细胞癌中的表达与预后不良相关。
J Exp Clin Cancer Res. 2009 Feb 16;28(1):20. doi: 10.1186/1756-9966-28-20.